CVI HBV 002Alternative Names: CVI-HBV-002
Latest Information Update: 04 Mar 2016
At a glance
- Originator Cha Vaccine Institute
- Class Hepatitis B vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Hepatitis B
Most Recent Events
- 18 Nov 2014 Phase-I/II clinical trials in Hepatitis B (Treatment-experienced) in South Korea (IM) (NCT02693652; KCT0001249)